For decades, cognitive decline in individuals over the age of 80 has been commonly dismissed as an unavoidable consequence of aging. This long-standing perception has shaped clinical approaches, often leading to the assumption that memory impairments in very old adults are simply natural and not worthy of detailed medical scrutiny. However, emerging research is challenging this paradigm by demonstrating that neurodegenerative diseases like Alzheimer’s disease (AD) play a crucial role in cognitive deterioration among this population, and that precise diagnostic tools can uncover these underlying causes with significant implications for treatment and prognosis.
A groundbreaking observational study conducted by the Sant Pau Research Institute (IR Sant Pau) and published in the journal Neurology delves deeply into the role of Alzheimer’s disease biomarkers in very old adults, specifically those aged 80 and above diagnosed with mild cognitive impairment (MCI). Utilizing sophisticated biomarker analysis from cerebrospinal fluid and blood, researchers have established that Alzheimer’s disease biology is not only prevalent in this age group but also correlates strongly with accelerated cognitive decline and increased likelihood of progression to dementia.
This research stands firmly against the widespread skepticism that biomarkers lose diagnostic value in the oldest old due to the confounding effects of multiple coexisting pathologies. Contrary to this belief, the study reveals that, even among highly complex clinical presentations typical of advanced age, identifying Alzheimer’s pathology through biomarkers offers robust, actionable insights into disease progression and patient outcomes, paving the way for improved clinical decision-making.
One of the most pertinent challenges in managing cognitive decline in the elderly is the inherent difficulty of accurately diagnosing Alzheimer’s disease based solely on clinical symptoms. Older adults are frequently assessed without biomarker support, resulting in diagnostic uncertainty. This is in part due to the frequent coexistence of various neurodegenerative and vascular conditions that create a heterogeneous clinical picture, making differential diagnosis challenging and often leading to therapeutic nihilism—a reluctance to pursue aggressive treatment due to diagnostic ambiguity.
The study highlights that as patients age, clinical assessments lose sensitivity; cognitive test performances—especially memory tests—show overlapping results between patients with and without Alzheimer’s disease biology. This overlap diminishes the power of traditional clinical evaluation to distinguish Alzheimer’s disease from other causes of cognitive impairment, underscoring the need for biomarker-supported diagnostics to enhance accuracy, particularly in the mild stages of impairment.
Dr. Chiara Ceriello, a geriatrician and lead author of the study, underlines the complexity of dementia diagnoses in the very old. Her findings indicate that about half of the memory impairment cases lack pure Alzheimer’s pathology, underscoring the challenge clinicians face in disentangling multifactorial contributors to cognitive decline without biomarker data. This diagnostic ambiguity complicates prognosis and management, reinforcing the importance of precision medicine approaches adapted to this age segment.
The Sant Pau study incorporated 167 participants aged 80 years and above with MCI, systematically investigating them through the SPIN cohort—one of the foremost clinical research cohorts targeting neurodegenerative diseases. Remarkably, nearly 70% exhibited biomarkers indicative of Alzheimer’s disease pathology, as evidenced by elevated cerebrospinal fluid p-Tau181 to β-amyloid ratios and corresponding elevations in the blood biomarker p-Tau217. While initial cognitive differences were subtle, their trajectories diverged significantly over time, with biomarker-positive individuals experiencing substantially faster cognitive deterioration.
Quantitatively, those with Alzheimer’s disease pathology demonstrated an average annual decline of 0.47 points on the Mini-Mental State Examination (MMSE) compared to 0.18 points per year among those without such biomarkers. Although seemingly modest annually, this disparity compounds, culminating in markedly accelerated cognitive impairment and diminishing functional independence. Importantly, biomarker positivity also conferred a significantly heightened risk of conversion to overt dementia during the follow-up period.
Of particular note is the prognostic utility of blood-based biomarkers such as p-Tau217. This biomarker not only reflects the presence of Alzheimer’s pathology but provides critical information on disease progression dynamics. Elevated p-Tau217 levels were linked to nearly a 50% increase in risk for dementia development, emphasizing the future potential of blood assays as both diagnostic and prognostic tools in routine clinical practice.
Dr. Ignacio Illán-Gala, neurologist and co-author, emphasizes the clinical relevance of these findings: although early cognitive symptoms overlap across groups, the crucial differentiation emerges in disease trajectory—the Alzheimer’s biology-positive patients exhibit a more aggressive decline, underscoring the importance of identifying the underlying pathology early to optimize patient management and improve quality of life.
Clinicians, particularly those working with geriatric populations, stand to benefit from integrating biomarker data into their assessment protocols. Knowledge of Alzheimer’s disease biology enables healthcare providers to refine diagnoses, anticipate progression trajectories more accurately, and customize care plans to better meet patient needs. This includes more informed monitoring strategies and proactive family counseling, which are especially crucial as older adults face increasing vulnerability to cognitive and functional deterioration.
Perhaps the most transformative advance emerging from this work is the validation of blood-based biomarkers like p-Tau217 for clinical application. Unlike invasive or costly procedures such as lumbar puncture or amyloid PET scanning, blood tests present a simpler, scalable, and more patient-friendly diagnostic option. This has significant implications for expanding biomarker use in routinely strained geriatric services, enabling broader, systematic approaches to Alzheimer’s disease diagnosis among the oldest cohorts.
Dr. Ceriello underscores that while biomarkers are invaluable, their interpretation must be contextualized within the broader clinical picture—including assessments of frailty, comorbidities, and baseline functional status—to ensure accurate, individualized care planning. Precision medicine, she argues, transcends age boundaries; even the very old benefit profoundly from targeted diagnostics that can influence therapeutic choices and optimize quality of life.
Furthermore, given the advent of emerging disease-modifying therapies capable of halting or slowing Alzheimer’s disease progression, early and accurate identification of patients with Alzheimer’s biology has never been more critical. Timely diagnosis in the very old could open avenues for these new interventions, which hold promise for altering the course of cognitive decline and extending autonomy in this vulnerable population.
Addressing cognitive concerns openly and proactively resonates deeply within the clinical community and among older adults themselves. As Dr. Illán-Gala notes, there is a growing number of octogenarians and nonagenarians seeking clarity on memory changes and prognosis. The inclusion of biomarker-informed diagnostics meets this demand, enabling clinicians to provide evidence-based answers and compassionate care tailored to the unique challenges of aging.
In sum, this study firmly establishes that Alzheimer’s disease biomarkers retain significant diagnostic and prognostic value well into advanced age. By leveraging these tools, the medical community can finally move past outdated assumptions, ushering in an era of precision geriatric neurology that acknowledges the complexity of cognitive decline but also empowers clinicians and patients with clearer understanding and hope.
Subject of Research: People
Article Title: Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old
News Publication Date: 17-Jun-2026
Web References: http://dx.doi.org/10.1212/WNL.0000000000218180
Image Credits: IR Sant Pau
Keywords: Alzheimer disease, Biomarkers, Neurodegenerative diseases, Cognitive decline, Mild cognitive impairment, Blood-based biomarkers, p-Tau217, Neurobiology of Dementias, Geriatric neurology, Precision medicine
Tags: age-related cognitive impairment researchAlzheimer’s disease and agingAlzheimer’s disease biomarkers in elderlyAlzheimer’s disease in oldest oldblood biomarkers for Alzheimer’scerebrospinal fluid biomarker analysiscognitive decline in adults over 80early diagnosis of cognitive deteriorationimpact of biomarkers on prognosisMild Cognitive Impairment diagnosisneurodegenerative disease detectionprogression from MCI to dementia
